DXCM Stock Recent News
DXCM LATEST HEADLINES
DexCom, Inc. (NASDAQ:DXCM ) 2025 Wells Fargo Healthcare Conference September 3, 2025 2:15 PM EDT Company Participants Jacob Leach - President & COO Jereme Sylvain - Executive VP, CFO & Chief Accounting Officer Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst Welome back. I am Larry Biegelsen, medical device analyst at Wells Fargo.
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock?
Shares of DexCom (DXCM 0.02%), a medical device specialist, have lagged the market this year. However, the true test of a company isn't how it performs over a relatively short period, such as eight months.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: The 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025 at 2:15 pm (EDT) The Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 2:00 pm (EDT) Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for futur.
DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.
Despite President Donald Trump's trade wars and concerns about a possible recession, equity markets have performed relatively well this year, with the S&P 500 (^GSPC -0.29%) up 10% since January. Some corporations, however, have not been as fortunate, including PayPal (PYPL -0.20%) and DexCom (DXCM 1.23%), both of which have underperformed the market due to company-specific issues.
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc. (NASDAQ: DXCM) on behalf of long-term stockholders following a class action complaint that was filed against DexCom on August 21, 2024 with a Class Period from January 8, 2024 to July 25, 2024. Our investigation concerns whether the board of directors of DexCom have breached their fiduciary duties to the company.
CNBC's "The Exchange" team discusses the potential of tariffs on pharmaceuticals, U.S. manufacturing and more with Dexcom CEO and chairman Kevin Sayer.
